tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Avadel Pharmaceuticals reports Q2 EPS 10c, consensus 3c

Reports Q2 revenue $68.129M, consensus $60.28M. “LUMRYZ strengthened its market position and delivered accelerated growth in revenue, positive cash flow and momentum in the second quarter, supported by its strong and growing foundation of prescribers and patients and our 2025 commercial investments,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals (AVDL). “Our commercial investments and execution have driven favorable uptake, growing reimbursed patients on therapy, and improved persistency trends generating quarterly net income for the first time since the launch of LUMRYZ in 2023. As such, these encouraging trends give us confidence to raise our guidance, and we now expect full-year revenues to be in the range of $265 – $275 million. With the recent appointment of Susan Rodriguez as our Chief Operating Officer and our enhanced commercial execution, we continue to identify additional opportunities to build on this momentum and capitalize on the differentiated profile of LUMRYZ to become the oxybate of choice for providers and patients.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1